CN-122005720-A - Application of Tibetan medicine renqing conventional sense and preparation thereof in preparation of medicines for preventing and treating ulcerative colitis

Abstract

The invention belongs to the field of medicines, and discloses application of Tibetan medicine renqing conventional sense and a preparation thereof in preparing medicines for preventing and treating ulcerative colitis. Animal models prove that the renqing normal sense can improve the clinical symptoms of ulcerative colitis, relieve pathological damage of colon tissues and down regulate the expression of inflammatory factors of the colon tissues. The experimental result shows that the interference of the renqing usual sense with the dose of 205-410 mg/kg/day can obviously slow down the weight reduction trend of a model mouse, obviously reduce the colon shortening degree and the disease activity index, can effectively reduce the damage of the epithelium of the mucous membrane of the colon, the damage of the crypt structure and the inflammatory cell infiltration, and obviously down regulate the gene expression level of key pro-inflammatory cytokines such as TNF-alpha and IL-1 beta in colon tissues.

Inventors

• DOU JIE
• Zhuo ga
• MO GE
• ZHAO YUMENG
• CIRENDUOJI
• GONG LI
• ZHU LIJUN
• WEI YOUXIU
• GUO MIN
• Dunzhu Danda

Assignees

• 中国药科大学

Dates

Publication Date

20260512

Application Date

20260319

Claims (9)

1. 1. The application of Tibetan medicine renqing is in preparing a medicine for preventing and treating ulcerative colitis.
2. 2. The application of Tibetan medicine renqing conventional sense and its preparation in preparing medicine for preventing ulcerative colitis.
3. 3. The application of Tibetan medicine renqing is in preparing medicaments for treating ulcerative colitis.
4. 4. The use according to any one of claims 1 to 3, wherein the swertia pseudolaris preparation is a pill.
5. 5. The use according to any one of claims 1 to 3, wherein the administration of the Tibetan medicine renqing usual and its preparation is oral administration.
6. 6. Use according to any one of claims 1 to 3, wherein the Tibetan medicine renqing is administered prophylactically in a dosage ranging from 205 mg/kg/day to 410 mg/kg/day.
7. 7. The use of Tibetan medicine renqing is in the preparation of medicine for regulating the expression level of key proinflammatory cytokine gene in colon tissue.
8. 8. The use of claim 7, wherein the pro-inflammatory cytokine is TNF- α.
9. 9. The use of claim 7, wherein the pro-inflammatory cytokine is IL-1 β.

Description

Application of Tibetan medicine renqing conventional sense and preparation thereof in preparation of medicines for preventing and treating ulcerative colitis Technical Field The invention belongs to the field of medicines, and in particular relates to application of Tibetan medicine renqing conventional sense and a preparation thereof in preparing medicines for preventing and treating ulcerative colitis. Background The Tibetan medicine renqing is a classical Tibetan medicine compound preparation. Has effects in clearing away heat and toxic materials, regulating three causes (Dragon, chiba, bacon), promoting blood circulation, dispelling blood stasis, invigorating spleen, regulating stomach function, nourishing body constitution, and eliminating abnormal mucus and inflammatory exudation. In the clinic of traditional Tibetan medicine, renqing is mainly used for treating various diseases caused by three causes of disorder, heat toxin accumulation and Mubuh disease (corresponding to digestive system inflammation, ulcer and disorder syndrome in Tibetan medicine), including old gastroenteritis, gastric and duodenal ulcer, atrophic gastritis, poisoning, old fever, anthrax, gangrene, furuncle and carbuncle, pyocutaneous disease, rheumatalgia, and pain and physical weakness related to certain tumors. It is regarded as a comprehensive conditioning treasure capable of balancing the whole state of organism and enhancing disease resistance. The Renqing (Chinese pharmacopoeia, edition one 2020) is a black watered pill, which has slightly fragrant smell, sweet, slightly bitter and astringent taste. The pharmacopoeia defines the dosage (1 pill for oral administration, 1 pill for one time, 1 time a day) and specification (1 g weight of each pill), and the storage condition is standardized. Ulcerative colitis is an inflammatory bowel disease, the pathological feature of which is a continuous, diffuse inflammation of the colonic mucosa and submucosa, with lesions usually originating in the rectum and extending proximally continuously. The main clinical manifestations of the disease include diarrhea, mucopurulent bloody stool, abdominal pain and tenesmus, which occur continuously or repeatedly. As a chronic recurrent disease, ulcerative colitis, if not effectively controlled, can cause disease repetition, cause persistent abdominal pain, diarrhea and hematochezia, seriously affect the nutritional status, social function, psychological status and quality of life of patients, and significantly increase hospitalization rate, operation rate and colorectal cancer risk. Currently, there is no method for radically treating ulcerative colitis, and existing clinical treatment methods for ulcerative colitis include aminosalicylic acid preparations (such as 5-aminosalicylic acid), glucocorticoids (oral prednisone and intravenous methylprednisone), traditional immunosuppressants (such as azathioprine and 6-mercaptopurine), biological preparations (such as infliximab, adalimumab and vedelizumab) and the like, and aims to inhibit abnormal immune response and relieve intestinal inflammation. However, long-term or repeated use of these drugs often comes with a range of problems including, but not limited to, the risk of infection by immunosuppression, steroid-related adverse effects, primary or secondary failure to respond, and possible immunogenicity and infusion reactions by the biological agent. Therefore, there is a great clinical need to develop new therapeutic drugs for patients with ulcerative colitis to break through the limitations of current therapies and improve the long-term prognosis and quality of life of patients. The existing clinical research evidence shows that renqing usually shows a definite synergistic effect in the treatment of chronic atrophic gastritis. A clinical observation shows that on the basis of standard tetrad therapy for eradicating helicobacter pylori, the combination of renqing is often used, and the clinical symptom relief rate and the pathological improvement rate of patients can be improved. In addition, the Chinese herbal medicine compound preparation is used for treating atrophic gastritis by combining with Chinese herbal medicine compound preparation such as dendrobium nobile lindl-liujun decoction and the like, and also shows the synergistic advantage of the green kernel in improving the atrophic gastritis. In an experimental animal model, the renqing can effectively improve the gastric hypodynamic state of rats and promote gastrointestinal coordination movement, and simultaneously, the renqing also has a protective effect on a stress gastric ulcer model. Disclosure of Invention The inventor finds that the Tibetan medicine kernel green sense can be used for preventing and treating ulcerative colitis. This finding is surprising, because it was not predicted that the known drugs for treating gastritis or gastric ulcer can be used for preventing ulcerative colitis, gastritis or gastric ulcer are all dise